MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-β/Smad2/STAT3/STAT5 pathway

Sun, Wei; Ma, Yanyun; Chen, Peng; Wang, Dong

doi:10.3892/mmr.2015.3181

Cited by 46 publications

(37 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sun et al [36] reported that miR-10a-5p may be a potential target for improving the effectiveness of lung cancer chemotherapy via regulation of the TGF-β/Smad2/ STAT3/STAT5 pathway. Previous published research has highlighted that miR-10a-5p was significantly markedly overexpressed and influenced the chemotherapy response in NPM1 mut AML, which may exert its biological properties in AML by interfering with the p53 machinery, which is partly regulated by MDM4 [13,14,30].…”

Section: Discussionmentioning

confidence: 99%

Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia

Zhi

Xie²,

Wang³

et al. 2015

Int J Hematol

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a type of small non-coding RNA molecule that play important roles in tumor initiation, chemotherapy response, promotion, and progression by negatively interfering with gene expression. The aim of the present study was to investigate the serum expression status and explore the prognostic significance of miR-10a-5p in acute myeloid leukemia (AML). The serum expression level of miR-10a-5p in de novo AML was significantly higher, compared with that in controls. The area under the receiver operator characteristic (ROC) curve was of 0.831 in the diagnostic value of miR-10a-5p. In the complete remission (CR) group, the serum expression level of miR-10a-5p was similar to that of healthy subjects and demonstrated a significant downtrend when compared to that on the day of diagnosis. Nevertheless, miR-10a-5p expression was found to significantly increase in cases of relapsed AML when compared individually to the CR population. On analysis of the association of miR-10a-5p expression with the clinical characteristics at diagnosis in AML patients, lower CR rates occurred more frequently in the high-expression group. In addition, high miR-10a-5p expression was associated with poorer overall survival (OS). These data suggest that miR-10a-5p may serve as a biomarker useful to improving the management of AML patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia

Zhi

Xie²,

Wang³

et al. 2015

Int J Hematol

View full text Add to dashboard Cite

show abstract

“…As one previous study show that down-regulated STAT3 expression can resulted in reduced β-catenin mRNA and protein levels [38], and another study reported that BAMBI knockdown can significantly decrease the expression of β-catenin mRNA and suppress metastasis of gastric cancer cells [39]. However, miR-10a silencing may reverses cisplatin resistance in human lung cancer cell line via the TGF-β/Smad2/STAT3/STAT5 pathway [40]. Thus, we speculate that miR-10a may indirectly affect the β-catenin mRNA expression by targeting STAT3 and/or BAMBI, and this will be further investigate in our future research.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-10a Influences Osteoblast Differentiation and Angiogenesis by Regulating β-Catenin Expression

Zhang

Zhao

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Elucidation of the molecular mechanisms governing osteoblast differentiation and angiogenesis are of great importance for improving the treatment of bone-related diseases. In this study, we examined the role of microRNA (miR)-10a in the differentiation of MC3T3-E1 cells and pro angiogenic activity of mouse umbilical vein endothelial cells (MUVECs). Methods: The murine pre-osteoblast cell line MC3T3-E1 and MUVECs were used in the experiment. After transfected with miR-10a mimics or inhibitors, with or without LiCl pretreatment, the miR-10a, ALP, Runx2, Osx, OC and Dlx5 expression were assessed by RT-PCR. MC3T3-E1 cells were cultured with BMP2 to differentiate into bone cells, osteogenic differentiation of MC3T3-E1 cells were detected by ALP and ARS staining. Cell viability were analyzed by MTT and the protein expression of β-catenin, LEF1, cyclinD1, MMP2, and VEGF were detected by Western blotting; VEGF and VE-cadherin release were assessed by ELISA, and the migration of MUVECs, as well as tube formation were also detected. Results: MiR-10a expression was obviously down-regulated during osteogenic differentiation. Overexpression of miR-10a inhibited osteogenic differentiation of MC3T3-E1 cells, effectively decreasing MUVECs proliferation, migration, VEGF expression, VE-cadherin concentrations, and tube formation in vitro, whereas miR-10a silence enhanced those processes. Further mechanism assays demonstrated that overexpression of miR-10a reduced the β-catenin at both protein and transcription level, while pretreatment with Wnt signaling activator Licl partially attenuated the suppression effects of miR-10a overexpression on osteoblast differentiation and angiogenesis. Conclusion: Our findings imply that miR-10a plays a suppressive role in osteoblast differentiation of MC3T3-E1 cells and pro angiogenic activity of MUVECs by regulating the β-catenin expression, representing a novel and potential therapeutic target for the treatment of bone regeneration-related diseases.

show abstract

“…Up-regulation of Let-7c sensitizes A549/DDP cells to CDDP by targeting ABCC2 [43]. Moreover, miR-10a, miR-106a and miR-134 can regulate different members of MDR to affect the responses of lung adenocarcinoma cells to CDDP [44][45][46].…”

Section: Mirnas Involved In Regulation Of Drug Transportsmentioning

confidence: 99%

MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer

Chen

Gao

Zhang

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Cisplatin (CDDP) is one of the most effective broad-spectrum anticancer drugs, which has been employed for the treatment of lung cancer. The development of CDDP resistance is a major problem of tumor chemotherapy. MicroRNAs (miRNAs) are an abundant class of small non-protein-coding RNAs, involved in the initiation and progression of human cancer. Increasing evidence has shown that dysregulation of miRNAs is involved in chemo resistance of tumor cells to anti-cancer drugs, including CDDP. This article summarizes current research involving miRNAs as regulators of key target genes for CDDP resistance in lung cancer. Potential use of targeting miRNAs can lead to miRNA-based therapies, which will be helpful for overcoming drug resistance and developing more effective personalized anti-cancer treatment strategies in human lung cancers.

show abstract

MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-β/Smad2/STAT3/STAT5 pathway

Cited by 46 publications

References 19 publications

Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia

Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia

MicroRNA-10a Influences Osteoblast Differentiation and Angiogenesis by Regulating β-Catenin Expression

MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer

Contact Info

Product

Resources

About